UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating
Analysts' Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Barclays: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $80.00 to $76.00.
Gilead Sciences Analyst Ratings
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80
Gilead Sciences: Hold Rating With Cautious Outlook Amidst Market Challenges and Growth Uncertainties
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
Royal Bank of Canada: Maintaining the Gilead Sciences (GILD.US) rating, adjusted from being equal to the general market to being equal to the general market, and the target price was adjusted from $76.00 to $74.00.
RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $74
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)
Needham: Reiterates Gilead Sciences (GILD.US) holds the rating.
Gilead Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
HSBC: Upgraded Gilead Sciences (GILD.US) rating, adjusted from holdings reduction to holding rating, target price $69.00.
No Data